What is the expected timeline for Eli Lilly's orforglipron approval and launch in China, according to company executives?

Eli Lilly Executive Vice President Patrik Jonsson told Reuters that the launch timing for orforglipron in China could be 'anything from late 2026 to early 2027'; the company submitted a marketing application for the once-daily oral GLP-1 pill to China's National Medical Products Administration at the end of 2025.

How does Eli Lilly's regulatory progress with orforglipron in China compare to Novo Nordisk's plans for Wegovy?

Eli Lilly has moved first in China, having submitted a marketing application for orforglipron at the end of 2025, while Novo Nordisk plans to seek Chinese regulatory approval for Wegovy 'very soon', according to CEO Mike Doustdar.

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

Jun 23, 2026

Eli Lilly executives state their oral GLP-1 drug orforglipron may gain China approval between late 2026 and early 2027. Rival Novo Nordisk also plans to seek approval soon as competition grows in the weight-loss drug market.

reuters

2026-06-11

Some US Employers to Drop Coverage of GLP-1 Obesity Drugs in 2027 as Use Increases

2026-06-23

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

FAQ